SI
PTCT icon

Stirlingshire Investments’s PTC Therapeutics PTCT Stock Holding History

Stirlingshire Investments’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,718
Closed -$253K – 246
2026
Q1 		$253K Buy
3,718
+131
+4% +$9.28K 0.22% 155
2025
Q4 		$272K Buy
+3,587
New +$261K 0.24% 125

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Stirlingshire Investments's PTCT Position: Q2 2026 in Review

Stirlingshire Investments sold out of PTC Therapeutics (PTCT) in Q2 2026, closing a stake of 3,718 shares — an estimated $253K sold.

Stirlingshire Investments first reported a position in PTCT in Q4 2025 and held it in 2 quarters. The position peaked at $272K in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Stirlingshire Investments reported no remaining PTC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Stirlingshire Investments sold 3,718 PTC Therapeutics shares in Q2 2026, an estimated $253K.
  • Stirlingshire Investments first reported a position in PTC Therapeutics in Q4 2025 and held it in 2 quarters.
  • Stirlingshire Investments's PTC Therapeutics position peaked at $272K in Q4 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Stirlingshire Investments's 13F filing for Q2 2026, filed 31 Jul 2026.